Vutrisiran’s Benefits Sustained Over 18 Months in HELIOS-A Trial

Vutrisiran’s Benefits Sustained Over 18 Months in HELIOS-A Trial

311509

Vutrisiran’s Benefits Sustained Over 18 Months in HELIOS-A Trial

The benefits of Vutrisiran in reducing neurologic impairment and overall disability, and improving the quality of life in adults with familial amyloid polyneuropathy (FAP) were sustained over 18 months, according to new data from the ongoing Phase 3 HELIOS-A trial. “These results build on the positive vutrisiran data shared earlier this year and suggest that the reduction of neurologic impairment and improvement in quality of life in patients with [FAP] observed as early as nine…

You must be logged in to read/download the full post.